Tag: fund

VICTORIA, Seychelles, June 12, 2025 (GLOBE NEWSWIRE) -- MEXC, a leading global cryptocurrency exchange, has unveiled a groundbreaking $100 million Guardian Fund to enhance user safety and trust across its platform. This fund is designed to provide a strong safeguard for users facing severe security threats, such as large-scale exploits, targeted attacks, or unforeseen system vulnerabilities. In a move toward greater accountability, MEXC has made the fund fully transparent by disclosing wallet addresses publicly—setting a new industry standard for proactive risk management and user protection.

Paris, France – June 12, 2025

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, has raised $19 million in a new private financing to advance its lead clinical program EO2463 OncoMimics™ immunotherapy to treat indolent non-Hodgkin lymphoma (iNHL). The new funds will be used to expand and finalize the ongoing Phase 1/2 SIDNEY clinical trial of EO2463 and prepare the candidate for a registrational trial.

빅토리아, 세이셸, June 12, 2025 (GLOBE NEWSWIRE) -- 암호화폐 거래소이자 웹3.0 선도기업인 Bitget이 사용자 보안 펀드인 보호 펀드 (Protection Fund)가 5월에 7억 2,510만 달러로 최고치를 기록하며 설립 이래 최고 수치를 달성하게 되었다고 2025년 5월 보고서를 발표했다. 극심한 시장 상황에서 사용자 자산을 보호하기 위해 설계된 이 펀드는 한 달 내내 꾸준한 성장세를 보이며 월 평균 6억 7,350만 달러의 가치를 기록했다.

Leuven, Belgium, June 12, 2025 – AstriVax Therapeutics NV, a clinical stage immunotherapy company developing novel treatments for chronic infections based on its proprietary Launch-iT technology, announced today the appointment of Dieter Weinand as Chair of the Board of Directors, effective June 12, 2025. Mr. Weinand is the former Chief Executive Officer of Bayer Pharma AG with more than 25 years of experience as a senior business leader in the pharmaceutical industry. He takes over from Dr. Jeanne Bolger, who served as Chair since 2022 and will remain on the Board as a non-executive independent director.

NEW YORK, NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the “Company”) announced today that it has deposited into the Company’s trust account (the “Trust Account”) an aggregate of $874.78 to fund the one-month extension from June 11, 2025 to July 11, 2025. This deposit was funded via a convertible promissory note with a principal amount of up to $180,000 issued by the Company to Scilex Holding Company (Nasdaq: SCLX, “Scilex”), which bears no interest and is repayable on the earlier of the effective date of the consummation of the Company’s initial business combination or the date of the liquidation of the Company. Upon the closing of a business combination, the note is convertible, at Scilex’s discretion, into the Company’s Class A ordinary shares at a conversion price of $10.00 per share. Any future drawdowns of the remaining $56,920.74 principal amount available under the convertible promissory note are expected to fund future one-month extensions as necessary to provide additional time for the Company to complete a business combination.

Sheridan, WY, June 11, 2025 (GLOBE NEWSWIRE) -- Breakthrough Nura Wallet technology turns crypto staking from 50-exchange nightmare into simple one-click profit machine

Nura Labs, LLC today filed a game-changing patent that could unlock $180 billion in trapped DeFi value. The Company's breakthrough AI technology transforms impossibly complex crypto staking into automated profit generation through the world's first intelligent wallet.

Patent pending — U.S. Provisional Application No. 63/819,482 protects revolutionary algorithms that automatically optimize staking across hundreds of protocols while users simply hold their crypto in the Nura Wallet.

The $180 Billion Problem Finally Solved

Current crypto staking forces users to become day traders across dozens of platforms simultaneously. This complexity locks out 95% of crypto holders from earning passive income on their assets, leaving massive profits on the table. 

"We just eliminated the biggest barrier in crypto," said the Nura Labs team. "The Nura Wallet embeds institutional-grade AI that acts like a personal hedge fund manager, automatically maximizing yields while users sleep."

Patent-Protected Technology Advantage

The 37-claim patent covers three breakthrough innovations:

● Protocol-Specific AI Models that understand each DeFi protocol's unique mechanics

● Predictive Yield Optimization that forecasts market scenarios for maximum returns

● Autonomous Cross-Protocol Management that seamlessly handles complex multi-chain operations

Explosive Performance Results

Real testing delivers game-changing results:

● 23% higher staking yields vs manual management

● 67% lower transaction costs through intelligent execution

● 89% less time required for portfolio optimization

● 2x better risk-adjusted returns through AI diversification

Massive Market Opportunity

With the DeFi market growing 300% annually and less than 10% user penetration due to complexity, Nura Labs is positioned to capture enormous market share through patent-protected technology that makes institutional-grade staking accessible to everyone.

Multiple Revenue Streams

The patent enables lucrative business opportunities:

● Technology licensing to major crypto platforms

● Direct Nura Wallet operations targeting millions of users

● Strategic partnerships with top DeFi protocols

Aggressive Growth Timeline

Q3 2025: Beta launch and strategic partnerships

Q4 2025: Major protocol integrations

Q1 2026: Public launch capturing mainstream market

Q2 2026: International expansion and institutional features

Investment Catalyst

This patent filing creates a defensible competitive moat around the most valuable innovation in DeFi infrastructure. Nura Labs seeks strategic investors and partners to capitalize on this massive market opportunity. 

"We've built the technology that finally makes crypto work for everyone," continued the team. "This patent protects our path to becoming the dominant wallet in the fastest-growing sector of finance."

Contact Information

Corporate Development: investors@nura.gg

Strategic Partnerships: partnerships@nura.gg

Media Inquiries: media@nura.gg

Nura Labs, LLC

30 N Gould St, STE R, Sheridan, WY 82801

Website: https://nura.gg/

Legal Notice

Patent pending — U.S. Provisional Application No. 63/819,482, filed on 06/06/25. Cryptocurrency investments involve substantial risk. Investment opportunities limited to accredited investors.

Disclaimer: The information provided in this press release is not a solicitation for investment, nor is it intended as investment advice, financial advice, or trading advice. It is strongly recommended you practice due diligence, including consultation with a professional financial advisor, before investing in or trading cryptocurrency and securities.

LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has entered into Incremental Amendment No. 2 (the “Second Amendment”) to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the “Existing Credit Agreement” and, as amended by the Second Amendment, the “Credit Agreement”).

New campus will expand specialty care and research for children from across the region